Pharmaceutical patents can drive up the costs of lifesaving medications. Hear what author and YouTube star John Green is doing to make tuberculosis drugs more accessible to the people who need them most.
Category: drug costs
KFF Health News’ ‘What the Health?’: Countdown to Shutdown
Congress appears to be careening toward a government shutdown, as a small band of House conservatives vow to block any funding for the fiscal year that begins Oct. 1 unless they win deeper cuts to health and other domestic programs. Meanwhile, former President Donald Trump continues to roil the GOP presidential primary field, this time with comments about abortion. Alice Miranda Ollstein of Politico, Rachel Cohrs of Stat, and Tami Luhby of CNN join KFF Health News chief Washington correspondent Julie Rovner to discuss these issues and more. Also, for “extra credit,” the panelists suggest health policy stories they read this week they think you should read, too.
Save Billions or Stick With Humira? Drug Brokers Steer Americans to the Costly Choice
Thousands of patients with autoimmune diseases who rely on Humira, with a list price of $6,600 a month, could get financial relief from new low-cost rivals. So far, the pharmacy benefit managers that control drug prices in America have not delivered on those savings.
KFF Health News’ ‘What the Health?’: Welcome Back, Congress. Now Get to Work.
Congress returns from its summer recess with a long list of tasks and only a few work days to get them done. On top of the annual spending bills needed to keep the government operating, on the list are bills to renew the global HIV/AIDS program, PEPFAR, and the community health centers program. Meanwhile, over the recess, the Biden administration released the names of the first 10 drugs selected for the Medicare price negotiation program.
5 Things to Know About the New Drug Pricing Negotiations
The Biden administration unveiled the first 10 drugs subject to price negotiations, taking a swipe at the pharmaceutical industry. But what does it mean for patients?
A Move to Cut Drug Prices Has Patients With Rare Diseases Worried
A Colorado board has named five drugs it will review for affordability and potential cost caps. But patients with cystic fibrosis worry they will lose access to a life-changing therapy.
A Peek at Big Pharma’s Playbook That Leaves Many Americans Unable to Afford Their Drugs
Brand-name drug prices in the U.S. — more than three times the price in other developed countries — are related neither to the amount of research and development required to bring them to market nor their therapeutic value, recent research shows. Have drugmakers overplayed their hand?
KFF Health News’ ‘What the Health?’: On Abortion Rights, Ohio Is the New Kansas
Nearly a year to the day after Kansas voters surprised the nation by defeating an anti-abortion ballot question, Ohio voters defeated a similar, if cagier, effort to limit access in that state. This week, they rejected an effort to raise the threshold for approval of future ballot measures from a simple majority, which would have made it harder to protect abortion access with yet another ballot question come November. Meanwhile, the number of Americans without health insurance has dropped to an all-time low, though few noticed. Joanne Kenen of the Johns Hopkins Bloomberg School of Public Health and Politico, Rachel Roubein of The Washington Post, and Emmarie Huetteman of KFF Health News join KFF Health News’ chief Washington correspondent, Julie Rovner, to discuss these issues and more. Also this week, Rovner interviews Kate McEvoy, executive director of the National Association of Medicaid Directors, about how the “Medicaid unwinding” is going, as millions have their eligibility for coverage rechecked.
Seeking Medicare Coverage for Weight Loss Drugs, Pharma Giant Courts Black Influencers
Novo Nordisk, the dominant company in the multibillion-dollar market for weight loss drugs, focuses on Black lawmakers and opinion leaders to spread the message that obesity is a chronic disease that needs treatment.
Survey: Americans Want Weight Loss Drugs Despite High Cost
A new poll reveals enthusiasm for a pricey new generation of weight loss drugs, but interest drops if users potentially have to deal with weekly injections, lack of insurance coverage, or a need to continue the medications indefinitely to avoid regaining weight.
